Article Per Year (5 Year)
p-Index From 2020 - 2025
0.659
P-Index
This Author published in this journals
All Journal Jurnal Respirologi Indonesia
Suryanti Dwi Pratiwi
Department Of Pulmonology And Respiratory Medicine, Faculty Of Medicine, Universitas Brawijaya
Health Professions Medicine & Pharmacology

Published : 4 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 4 Documents
Search

 1 
Correlation Between CEA Serum Level on NSCLC Patients with EGFR Mutation from Tissue and Plasma Sample Frenky Hardiyanto Hendro Sampurno; Suryanti Dwi Pratiwi; Ngakan Putu Parsama Putra
Jurnal Respirologi Indonesia Vol 42, No 2 (2022)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/jri.v42i2.299

Abstract

Background: Patients with NSCLC can have EGFR mutation and increased level of CEA. EGFR mutation test on NSCLC has very important role for EGFR tyrosine kinase inhibitor (TKI) therapy.CEA is also expected to predict treatment efficiency of EGFR-TKI therapy. Tumor tissue biopsy is an invasive method and has come constraints, despite the golden standard testing. Circulating tumor DNA (ctDNA) is a new and less invasive for detecting EGFR mutation using plasma sample. In this study, we investigated the relationship between serum CEA and EGFR mutations in tissue and plasma in NSCLC patient.Methods: This cross-sectional observational research was conducted in Dr. Saiful Anwar General Hospital Malang from August 2018 until July 2019, 76 NSCLC patients who had undergone test of EGFR mutation from tissue, ctDNA, and serum CEA level. Extracted DNA from plasma and tissue samples from citology or biopsy was checked for the EGFR mutation. The serum CEA levels were analyzed using electrochemical luminescence.Results: EGFR mutation from tissue samples positive detected on 34 subjects and ctDNA detected 19 subjects. Serum level of CEA >5 ng/ml was significantly associated with EGFR mutation from tissue sample (p=0.037) with an odds ratio of 2.778 (95% CI: 1.050-7.348), the area under curve for CEA was 68,8% and cut-off CEA 9.14 ng/ml. Serum level of CEA >5 ng/ml wasalso significantly associated with ctDNA (p=0.015) with an odds ratio of 4.8 (95% CI: 1.259-18.299), the area under curve for CEA was 78,1% and cut-off CEA 14.8 ng/ml.Conclusion: Serum CEA level has poor correlation with mutation of EGFR from tissue and moderate correlation with mutation of EGFR from ctDNA in NSCLC patients. Patients with increased level of CEA >5 ng/ml are 2.778 times more at risk to had EGFR mutation and 4.8 times more at risk to had ctDNA positive mutation.
The Effect of Pulmonary Rehabilitation on The Duration of Antibiotic Switches, IL-10 Levels and PEFR Values in Hospitalized Community Pneumonia Patients Mariyatul Khiptiyah; Iin Noor Chozin; Suryanti Dwi Pratiwi; Rahmad Rahmad; Harun Al Rasyid
Jurnal Respirologi Indonesia Vol 40, No 4 (2020)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/jri.v40i4.129

Abstract

Background: Pneumonia is an acute inflammation of the lung parenchyma and ranked third of 30 causes of death in the world. WHO estimates the death caused by pneumonia is 1.6 million per year. Long duration of antibiotic switches is associated with increased morbidity, nosocomial infections and costs of healthcare. This study aims to assess the effect of pulmonary rehabilitation with the duration of antibiotic switches and interleukin-10 (IL-10) levels of pneumonia patients in non-intensive care thus pulmonary rehabilitation can be routinely use as adjuvant therapy. Methods: The study was conducted in May-November 2019 at Saiful Anwar Hospital Malang, with 40 pneumonia patients in the non-intensive care and divided in two groups which contains of 20 patients. This study uses consecutive simple random sampling. In treatment group, pulmonary rehabilitation consists of breathing exercise, effective cough techniques, clapping, postural drainage and breathing muscle exercises with spirometry incentive tools. The pulmonary rehabilitation treatment was done by Medical Rehabilitation Department of Saiful Anwar Malang Hospital. IL-10 levels and PEFR values on the zero and fifth days of treatment were measured. Results: The duration of antibiotic switches received pulmonary rehabilitation was shorter 5.05 days (P
Preliminary Study: Increased Profile of PAI-1 in Lung Cancer Patients Receiving Chemotherapy Ria Siska Myrnasari; Triwahju Astuti; Suryanti Dwi Pratiwi
Jurnal Respirologi Indonesia Vol 38, No 1 (2018)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/jri.v38i1.139

Abstract

Background: Lung cancer has the highest mortality rate in the world. Lung cancer management requires biomarkers to evaluate the chemotherapy response. Levels of Plasminogen Activator Inhibitor-1 (PAI-1) in malignancy >14 ng/ml shows poor prognosis. Increased levels of PAI-1 are associated with stage, metastasis, and prognosis of lung cancer. The chemotherapy is thought to decrease PAI-1 levels. The aim this study is analyze the profile of PAI-1 levels before and after 3rd and 6th chemotherapy cycle and their changes by type of lung cancer and Response Evaluation Criteria in Solid Tumors (RECIST). Methods: This research was conducted from December 2016 to December 2017 at RSSA Malang. The study design was a cohort of 18 lung cancer patients. PAI-1 levels were measured by ELISA in 18 lung cancer stage III or IV patients before (PAI-1(1)) and after 3rd chemotherapy cycle (PAI-1(2)), and 9 patients after 6th chemotherapy cycle (PAI-1(3)). Average PAI-1 levels are presented in tables and graphs. Result: PAI-1(1) 2,151±0,564 ng/ml, PAI-1(2) 1,951±0,534 ng/ml, and PAI-1(3) 1,647±0,495 ng/ml. PAI-1 levels in non-small cell lung carcinoma (NSCLC) were 1.658±0.562 ng/ml and small cell lung carcinoma (SCLC) were 1.609±0.244 ng/ml. Levels of PAI-1(2) in partial response 1.784 ± 0.363 ng/ml, stable disease 1.980 ± 0.304 ng/ml, and progressive disease 2.020±0.635 ng/ml. Levels of PAI-1(3) in the partial response 1.427 ± 0.324 ng/ml and in progressive disease 2.085±0.532 ng/ml. Conclusions: PAI-1 levels in patients with stage III and IV lung cancer after chemotherapy were lower than before chemotherapy, and showed changes corresponding to the response according to RECIST. PAI-1 levels in NSCLC are higher than SCLC. (J Respir Indo 2018; 38(1): 48-56)
Analysis of Volatile Organic Compounds in the Exhaled Breath of COVID-19 Patients Tiar Oktavian Effendi; Iin Noor Chozin; Suryanti Dwi Pratiwi; Nanik Setijowati; Arinto Yudi Ponco Wardoyo
Jurnal Respirologi Indonesia Vol 43, No 4 (2023)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/jri.v43i4.394

Abstract

Background: It has been more than 2 years since COVID-19’s first cases were reported in 2019. Rapid diagnosis of COVID-19 is necessary to prevent its spread. A sample for COVID-19 testing is collected by naso-oro-pharyngeal swab. This procedure is often uncomfortable and requires a trained examiner. Exhaled breath contains thousands of volatile organic compounds (VOC), which are likely to change during infection. This study aimed to analyze the difference in VOC in the exhaled breath between COVID-19 and healthy subjects.Methods: A cross-sectional study was carried out, recruiting 90 confirmed cases of COVID-19 and 42 healthy subjects. A sample of exhaled breath was collected by using a 500-mL airbag in both groups. The sample was analyzed using an arrayed sensor breath analyzer to quantify the concentration of CO2, C7H8, C6H14, CH2O, NH4, TVOC, NO2, PM1.0, CO, NH3 ­and Acetone.Results: The medians of CO2, NH4, TVOC, NO2, and acetone were significantly lower in COVID-19 patients compared to healthy subjects (respectively 607.3 vs 1175.1; 0.0 vs 1.05; 0.05 vs 146.6; 0.04 vs 1.55; 0.0 vs 0.23) while C7H8, CH2O, CO, and NH3 were significantly higher (respectively 0.92 vs 0.0; 0.55 vs 0.01; 0.24 vs 0.0; 1.99 vs 0.67; all with P-value of <0.05.). Furthermore, we found NH4, acetone, NH3, and CO were positively correlated with the severity of COVID-19, while CO2 and TVOC were negatively correlated.Conclusion: COVID-19 patients emit distinctive VOC profiles in comparison with healthy subjects, and this is related to the severity of the disease.
Co-Authors Arinto Yudi Ponco Wardoyo Frenky Hardiyanto Hendro Sampurno Harun Al Rasyid Iin Noor Chozin Iin Noor Chozin Mariyatul Khiptiyah Nanik Setijowati Ngakan Putu Parsama Putra Rahmad Rahmad Ria Siska Myrnasari Tiar Oktavian Effendi Triwahju Astuti